Clinicians should be encouraged to prescribe cholinesterase inhibitors in a preventive manner in psychiatric patients susceptible to PTD-induced obesity and dysmetabolism, especially in the presence of schizophrenia or dementia-related cognitive impairments. This evidence concerns the gene BCHE and dementia.